Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) October 25 – 27, 2024!

For more Information and Register: Delaware ACC By the Sea: 2024 Chapter Meeting

Delaware Chapter of the American College of Cardiology


Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • ACC Issues Guidance For Diagnosing and Managing Myocarditis
    The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical practice. The 2024 ACC Expert Consensus Decision Pathway (ECDP) on Strategies and Criteria for the Diagnosis and Management of Myocarditis, published in JACC, includes a 5-step care pathway, […]
  • ACCEL Lite: Top Takeaways from 2024: Preventive Cardiology with Noel Bairey Merz, MD, FACC
    In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD FACC, discuss the Top Preventive Cardiology Takeaways from 2024. Dr. Bairey Merz discusses the SELECT and SUMMIT trials, the impact of cardiac interventions on the carbon footprint, and more.
  • State-of-the-Art Review Provides Strategies to Address Post-TAVR CDs and PPI
    A State-of-the-Art review published in JACC: Cardiovascular Interventions covers the epidemiology, clinical implications, risk factors and preventive strategies for new-onset conduction disturbances (CDs) and the need for permanent pacemaker implantation (PPI) after TAVR, which the authors note are a limitation of this therapy.
  • Poll: Mavacamten Use in Hypertrophic Cardiomyopathy
    A 63-year-old woman presents to the office for a second opinion on chronic chest pain and heart failure management. She has a medical history of mixed connective tissue disease, obstructive sleep apnea, hepatic steatosis, and long-standing hypertension diagnosed in her twenties.
  • Reshaping the Use of Transcatheter Mitral Valve Repair in Patients With Heart Failure: the RESHAPE-HF2 Trial
    The RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: Second Trial in Patients With Clinically Significant Functional Mitral Regurgitation) trial was an international, open-label, multicenter, randomized controlled trial designed to provide additional information regarding the safety and effectiveness of M-TEER in this patient population.